Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Sep 22, 2009

Unizyme and SARomics Ink Drug Discovery Deal for Inflammatory Diseases

  • Unizyme Laboratories in Denmark and SARomics in Sweden entered a research service collaboration related to inflammatory diseases. The aim is to discover novel lead compounds targeting dipeptidyl peptidase I (DPPI; cathepsin C).

    Unizyme will focus on identifying new small molecules that interact with and inhibit the function of DPPI. SARomics will apply its expertise in structure-based drug design to assist in the development of lead compounds.

    SARomics will also facilitate the interpretation of 3-D structures of DPPI interacting with small molecules provided by Unizyme. This information will be combined with high-speed computational methods, like high-performance ligand-receptor docking, to accelerate lead molecule identification.

     



Related content

Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »